Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.

Muqbil I, Chaker M, Aboukameel A, Mohammad RM, Azmi AS, Ramchandren R.

Heliyon. 2019 Aug 31;5(8):e02290. doi: 10.1016/j.heliyon.2019.e02290. eCollection 2019 Aug.

2.

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma.

Azmi AS, Li Y, Aboukameel A, Muqbil I, Philip PA, Mohammad RM.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1101. doi: 10.3390/cancers11081101.

3.

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.

Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS.

Oncotarget. 2018 Oct 19;9(82):35327-35342. doi: 10.18632/oncotarget.26239. eCollection 2018 Oct 19.

4.

Retraction notice to "Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells" [Cancer Lett. 319(2) (2012) 173-181].

Ali S, Ahmad A, Aboukameel A, Bao B, Padhye S, Philip PA, Sarkar FH.

Cancer Lett. 2018 Feb 1;414:313. doi: 10.1016/j.canlet.2017.11.030. No abstract available.

5.

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM.

Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10.

6.

Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.

Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS.

Small GTPases. 2019 Sep;10(5):367-377. doi: 10.1080/21541248.2017.1329694. Epub 2017 Jun 23.

PMID:
28641032
7.

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS.

Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.

8.

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

Muqbil I, Aboukameel A, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D, Zonder J, Azmi AS, Mohammad RM.

Cancer Lett. 2016 Dec 28;383(2):309-317. doi: 10.1016/j.canlet.2016.09.016. Epub 2016 Sep 28.

9.

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.

Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Nov 29;7(48):78883-78895. doi: 10.18632/oncotarget.12428.

10.

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.

Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM.

Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077.

11.

Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1.

Michelhaugh SK, Guastella AR, Varadarajan K, Klinger NV, Parajuli P, Ahmad A, Sethi S, Aboukameel A, Kiousis S, Zitron IM, Ebrahim SA, Polin LA, Sarkar FH, Bollig-Fischer A, Mittal S.

J Transl Med. 2015 Jul 15;13:227. doi: 10.1186/s12967-015-0596-8.

12.

Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?

Muqbil I, Wu J, Aboukameel A, Mohammad RM, Azmi AS.

Semin Cancer Biol. 2014 Aug;27:39-45. doi: 10.1016/j.semcancer.2014.06.003. Epub 2014 Jun 17. Review.

13.

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.

Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB, Mohammad RM.

Oncotarget. 2014 Jun 15;5(11):3444-54.

14.

Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling.

Ali S, Ahmad A, Aboukameel A, Ahmed A, Bao B, Banerjee S, Philip PA, Sarkar FH.

Cancer Lett. 2014 Aug 28;351(1):134-42. doi: 10.1016/j.canlet.2014.05.013. Epub 2014 May 16.

15.

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.

Rodrigueza WV, Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A.

Cancer Chemother Pharmacol. 2014 Jul;74(1):151-66. doi: 10.1007/s00280-014-2476-y. Epub 2014 May 16.

16.

Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer.

Bao B, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Aboukameel A, Mohammad R, Van Buren E, Azmi AS, Sarkar FH.

Stem Cells Dev. 2014 Aug 15;23(16):1947-58. doi: 10.1089/scd.2013.0551. Epub 2014 Jun 6.

PMID:
24734907
17.

Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.

Bao B, Azmi AS, Aboukameel A, Ahmad A, Bolling-Fischer A, Sethi S, Ali S, Li Y, Kong D, Banerjee S, Back J, Sarkar FH.

J Biol Chem. 2014 May 23;289(21):14520-33. doi: 10.1074/jbc.M113.532887. Epub 2014 Apr 9.

18.

Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies.

Al-Katib AM, Aboukameel A, Ebrahim A, Beck FW, Tekyi-Mensah SE, Raufi A, Ahmed Y, Mandziara M, Kafri Z.

Exp Hematol Oncol. 2014 Dec 19;3:31. doi: 10.1186/2162-3619-3-31. eCollection 2014.

19.

A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.

Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, Gulappa T, Cierpicki T, Owens S, Zhang T, Sun D, Stuckey JA, Mohammad RM, Nikolovska-Coleska Z.

Mol Cancer Ther. 2014 Mar;13(3):565-75. doi: 10.1158/1535-7163.MCT-12-0767. Epub 2013 Sep 9.

20.

Synthesis, characterization and anti-tumor activity of novel thymoquinone analogs against pancreatic cancer.

Yusufi M, Banerjee S, Mohammad M, Khatal S, Venkateswara Swamy K, Khan EM, Aboukameel A, Sarkar FH, Padhye S.

Bioorg Med Chem Lett. 2013 May 15;23(10):3101-4. doi: 10.1016/j.bmcl.2013.03.003. Epub 2013 Mar 14.

PMID:
23562242

Supplemental Content

Loading ...
Support Center